MY159491A - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents

Disubstituted phthalazine hedgehog pathway antagonists

Info

Publication number
MY159491A
MY159491A MYPI2010005097A MYPI2010005097A MY159491A MY 159491 A MY159491 A MY 159491A MY PI2010005097 A MYPI2010005097 A MY PI2010005097A MY PI2010005097 A MYPI2010005097 A MY PI2010005097A MY 159491 A MY159491 A MY 159491A
Authority
MY
Malaysia
Prior art keywords
hedgehog pathway
pathway antagonists
disubstituted phthalazine
phthalazine hedgehog
disubstituted
Prior art date
Application number
MYPI2010005097A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY159491A publication Critical patent/MY159491A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2010005097A 2008-04-29 2009-04-01 Disubstituted phthalazine hedgehog pathway antagonists MY159491A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4872908P 2008-04-29 2008-04-29

Publications (1)

Publication Number Publication Date
MY159491A true MY159491A (en) 2017-01-13

Family

ID=40846962

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010005097A MY159491A (en) 2008-04-29 2009-04-01 Disubstituted phthalazine hedgehog pathway antagonists

Country Status (22)

Country Link
US (1) US7981892B2 (enExample)
EP (1) EP2294061A2 (enExample)
JP (1) JP5442717B2 (enExample)
KR (1) KR101260116B1 (enExample)
CN (1) CN102066353B (enExample)
AU (1) AU2009241561B2 (enExample)
BR (1) BRPI0911618A2 (enExample)
CA (1) CA2723042A1 (enExample)
CO (1) CO6300945A2 (enExample)
CR (1) CR11741A (enExample)
DO (1) DOP2010000302A (enExample)
EA (1) EA201071248A1 (enExample)
EC (1) ECSP10010577A (enExample)
HN (1) HN2010002157A (enExample)
IL (1) IL208211A0 (enExample)
MA (1) MA32349B1 (enExample)
MX (1) MX2010011948A (enExample)
MY (1) MY159491A (enExample)
NZ (1) NZ588001A (enExample)
UA (1) UA102250C2 (enExample)
WO (1) WO2009134574A2 (enExample)
ZA (1) ZA201006695B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101260116B1 (ko) 2008-04-29 2013-05-02 일라이 릴리 앤드 캄파니 이치환된 프탈라진 헤지호그 경로 길항제
CA2742539C (en) 2008-11-03 2014-05-06 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
ES2392759T3 (es) 2008-11-17 2012-12-13 Eli Lilly And Company Piridazina tetrasustituida como antagonistas de la vía Hedgehog.
EA018372B1 (ru) 2008-11-17 2013-07-30 Эли Лилли Энд Компани Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AU2010322114B2 (en) * 2009-11-18 2014-07-31 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CA2878082A1 (en) 2012-09-17 2014-03-20 Duke University Smoothened modulators and methods of use thereof
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN107163028B (zh) * 2017-05-24 2019-07-12 东南大学 一种苯甲酰胺类Hedgehog抑制剂及其制备方法和应用
KR20230107568A (ko) 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법
US20240124451A1 (en) * 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO1999052534A1 (en) 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
EP1997494A3 (en) 2002-04-22 2009-06-10 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
JP5221952B2 (ja) 2004-05-08 2013-06-26 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 3−アリール−5,6−ジ置換ピリダジン類
KR20150002863A (ko) * 2004-09-02 2015-01-07 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
DK2137162T3 (en) * 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
CA2690378A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
KR101260116B1 (ko) 2008-04-29 2013-05-02 일라이 릴리 앤드 캄파니 이치환된 프탈라진 헤지호그 경로 길항제
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2742539C (en) 2008-11-03 2014-05-06 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
ES2392759T3 (es) 2008-11-17 2012-12-13 Eli Lilly And Company Piridazina tetrasustituida como antagonistas de la vía Hedgehog.
EA018372B1 (ru) 2008-11-17 2013-07-30 Эли Лилли Энд Компани Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
ECSP10010577A (es) 2010-11-30
CO6300945A2 (es) 2011-07-21
KR101260116B1 (ko) 2013-05-02
US20110046143A1 (en) 2011-02-24
CR11741A (es) 2011-01-05
EP2294061A2 (en) 2011-03-16
ZA201006695B (en) 2012-09-26
JP2011527666A (ja) 2011-11-04
CN102066353A (zh) 2011-05-18
MA32349B1 (fr) 2011-06-01
AU2009241561A1 (en) 2009-11-05
AU2009241561B2 (en) 2013-05-16
WO2009134574A2 (en) 2009-11-05
BRPI0911618A2 (pt) 2019-09-24
JP5442717B2 (ja) 2014-03-12
UA102250C2 (ru) 2013-06-25
MX2010011948A (es) 2010-12-14
CN102066353B (zh) 2013-12-11
HN2010002157A (es) 2014-09-08
CA2723042A1 (en) 2009-11-05
NZ588001A (en) 2012-06-29
WO2009134574A3 (en) 2014-09-04
IL208211A0 (en) 2010-12-30
US7981892B2 (en) 2011-07-19
DOP2010000302A (es) 2010-11-15
EA201071248A1 (ru) 2011-06-30
KR20100126580A (ko) 2010-12-01

Similar Documents

Publication Publication Date Title
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
EA201171367A1 (ru) Винилиндазолильные соединения
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MY153915A (en) Organic compounds
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MY186456A (en) Quinazoline carboxamide azetidines
IN2012DN02471A (enExample)
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
TW200700064A (en) Novel compounds
MX2009009693A (es) Metodos para activar irs-1 y akt.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
NZ593169A (en) Anticancer compounds
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
CY1114078T1 (el) Ανταγωνιστες διυποκατεστημενης φθαλαζινης του μονοπατιου hedgehog
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative